A Novel Strategy Conjugating PD-L1 Polypeptide With Doxorubicin Alleviates Chemotherapeutic Resistance and Enhances Immune Response in Colon Cancer

BACKGROUND: Modifying the structure of anti-tumor chemotherapy drug is of significance to enhance the specificity and efficacy of drug-delivery. A novel proteolysis resistant PD-L1-targeted peptide (PPA1) has been reported to bind to PD-L1 and disrupt the PD-1/PD-L1 interaction, thus appearing as an...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Maolin, Shu, Xing-sheng, Li, Meiqi, Zhang, Yilin, Yao, Youli, Huang, Xiaoyan, Li, Jianna, Wei, Pengfei, He, Zhendan, Lu, Jun, Ying, Ying
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631515/
https://www.ncbi.nlm.nih.gov/pubmed/34858817
http://dx.doi.org/10.3389/fonc.2021.737323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8631515/
https://www.ncbi.nlm.nih.gov/pubmed/34858817
http://dx.doi.org/10.3389/fonc.2021.737323

Ejemplares similares